Literature DB >> 27473574

Loss of AZGP1 as a Superior Predictor of Relapse in Margin-Positive Localized Prostate Cancer.

Hannah M Bruce1,2, Phillip D Stricker1,2,3, Ruta Gupta1,4,5, Richard R Savdie3, Anne-Maree Haynes1, Kate L Mahon1,5,6,7, Hui-Ming Lin1, James G Kench1,4,5, Lisa G Horvath8,9,10,11.   

Abstract

BACKGROUND: Positive surgical margins (PSMs) in localized prostate cancer (PC) confer a two- to three-fold increased risk of biochemical relapse (BR). Absent/weak AZGP1 expression and Gleason grade ≥4 at the margin are each independent predictors of BR in patients with PSMs. Our study aimed to determine whether the biomarkers AZGP1 expression and Gleason grade at the site of a PSM are significant independent markers of biochemical and clinical relapse (CR) when modeled together and whether one of these biomarkers may be superior in its capacity to predict outcome. <br> METHODS: A cohort of 275 consecutive patients with margin-positive localized PC following surgery were assessed for Gleason grade and AZGP1 expression at the PSM. BR-free survival was the primary end-point, while CR-free survival and PC-specific death were secondary endpoints. Kaplan-Meier Analysis and Cox Proportional Hazards Modeling were performed. <br> RESULTS: Absent AZGP1 expression was significantly associated with increased risk of BR (P = 0.001) and PC-specific death (P = 0.02). Gleason grade ≥4 at PSM was associated with BR (P = 0.02), CR (P = 0.003), and PC-specific death (P = 0.004). On multivariable analysis, absent AZGP1 expression remained an independent predictor of BR (HR 2.4, 95%CI 1.5-3.9, P < 0.001) when modeled with Gleason grade at margin (HR 1.3, 95%CI 0.9-1.9, P = 0.16), preoperative PSA (P = 0.002), seminal vesicle involvement (P = 0.002), extraprostatic extension (P = 0.001), Gleason score (P = 0.01), adjuvant treatment (P = 0.75), linear length of the involved margin (P = 0.001) and margin number (P = 0.09). <br> CONCLUSION: Absent AZGP1 expression is an independent predictor of BR in margin-positive localized PC and is associated with increased PC-specific mortality in a Phase II study. Absent AZGP1 expression was superior to Gleason grade at PSM in predicting relapse and should be incorporated into subsequent clinical trials of post-operative radiotherapy in men with margin-positive PC. Prostate 76:1491-1500, 2016.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  AZGP1; Gleason grade; localized prostate cancer; positive surgical margin; radiotherapy

Mesh:

Substances:

Year:  2016        PMID: 27473574     DOI: 10.1002/pros.23233

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  4 in total

1.  Low vitamin D status is associated with inflammation in patients with prostate cancer.

Authors:  Dong-Dong Xie; Yuan-Hua Chen; Shen Xu; Cheng Zhang; Da-Ming Wang; Hua Wang; Lei Chen; Zhi-Hui Zhang; Mi-Zhen Xia; De-Xiang Xu; De-Xin Yu
Journal:  Oncotarget       Date:  2017-03-28

2.  Zinc-α2-glycoprotein 1 promotes EMT in colorectal cancer by filamin A mediated focal adhesion pathway.

Authors:  Meiling Ji; Wenxiang Li; Guodong He; Dexiang Zhu; Shixu Lv; Wentao Tang; Mi Jian; Peng Zheng; Liangliang Yang; Zhipeng Qi; Yihao Mao; Li Ren; Yunshi Zhong; Yongjiu Tu; Ye Wei; Jianmin Xu
Journal:  J Cancer       Date:  2019-08-29       Impact factor: 4.207

3.  Integrated Analysis of RNA-Binding Proteins Associated With the Prognosis and Immunosuppression in Squamous Cell Carcinoma of Head and Neck.

Authors:  Guangsheng Hu; Qingshan Jiang; Lijun Liu; Hong Peng; Yaya Wang; Shuyan Li; Yanhua Tang; Jing Yu; Jing Yang; Zhifeng Liu
Journal:  Front Genet       Date:  2021-01-11       Impact factor: 4.599

4.  Diagnostic and prognostic factors in patients with prostate cancer: a systematic review.

Authors:  Katharina Beyer; Lisa Moris; Michael Lardas; Anna Haire; Francesco Barletta; Simone Scuderi; Megan Molnar; Ronald Herrera; Abdul Rauf; Riccardo Campi; Isabella Greco; Kirill Shiranov; Saeed Dabestani; Thomas van den Broeck; Sujenthiran Arun; Mauro Gacci; Giorgio Gandaglia; Muhammad Imran Omar; Steven MacLennan; Monique J Roobol; Bahman Farahmand; Eleni Vradi; Zsuzsanna Devecseri; Alex Asiimwe; Jihong Zong; Sara J Maclennan; Laurence Collette; James NDow; Alberto Briganti; Anders Bjartell; Mieke Van Hemelrijck
Journal:  BMJ Open       Date:  2022-04-04       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.